Literature DB >> 12812665

[Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].

Jin Lu1, Lan-ping Xu, Xiao-jun Huang, Huan Chen, Yao-chen Zhang, Han-yun Ren, Nai-lan Guo, Dao-pei Lu.   

Abstract

OBJECTIVE: To investigate the effects of IL-2R alpha chain (CD(25)) monoclonal antibody on severe steroid-refractory graft-versus-host disease (GVHD).
METHODS: Seventeen patients (18 times) with severe steroid-refractory GVHD were treated with intravenous drip of humanized CD(25) monoclonal antibody on day 1, 3 or 4, 8, 15 and 22. The cumulative scoring of GVHD and status of infection were observed, and laboratory tests, including blood counting and blood biochemical test were made before and 1, 4, 8, 15, 22, 29, 36, 43 and 50 days after the treatment.
RESULTS: (1) Eleven of the eighteen case-times (61.1%) got complete relief, five (27.8%) GVHD got partial relief, and two (11.1%) failed to get relief. (2) Seven case-times (33.3%) had infection. (3) Relapse of GVHD occurred in four of the eleven case-times with complete relief (36.4%). (4) No infusion-related reaction was observed.
CONCLUSION: The monoclonal antibody against IL-2 receptor alpha chain (CD(25)) has a marked effect upon severe steroid-refractory GVHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12812665

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  High frequencies of CD62L⁺ naive regulatory T cells in allografts are associated with a low risk of acute graft-versus-host disease following unmanipulated allogeneic haematopoietic stem cell transplantation.

Authors:  S-Y Lu; K-Y Liu; D-H Liu; L-P Xu; X-J Huang
Journal:  Clin Exp Immunol       Date:  2011-06-02       Impact factor: 4.330

2.  Mesenchymal stromal cells inhibit CD25 expression via the mTOR pathway to potentiate T-cell suppression.

Authors:  Hyun Seung Yoo; Kyuheon Lee; Kwangmin Na; Yong Xu Zhang; Hyun-Ja Lim; TacGhee Yi; Sun U Song; Myung-Shin Jeon
Journal:  Cell Death Dis       Date:  2017-02-23       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.